InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,527.49
(
-1.13%
)
Post# of 253510
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120661
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 169352

Tuesday, 11/05/2013 9:11:50 AM

Tuesday, November 05, 2013 9:11:50 AM

Post# of 253510

…GILD is stretching its DAA regimens to shorten the treatment to 6 weeks.

Not likely, IMO. On GILD’s 3Q13 CC, Kevin Young, chief commercial officer, said (http://seekingalpha.com/article/1785222-gilead-sciences-ceo-discusses-q3-2013-results-earnings-call-transcript ):

Just to chip in with a commercial angle here: …if you move from three months to two months, that's clearly a step change and an advantage… going from eight weeks to six weeks doesn't really give you that much more… I don't think carving off an extra two weeks is that big a differentiator when it comes to the commercial profile of the products.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up